Elizabeth A. Sellars
Associate Professor
faculty
Peds Pediatrics, College of Medicine
17 h-index
38 pubs
1,398 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Elizabeth A. Sellars investigates genetic factors contributing to human developmental disorders. Her research focuses on identifying deleterious, protein-altering variants in genes associated with phenotypes such as intellectual disability, mesomelic dysplasia, horseshoe kidney, epileptic encephalopathy, and neurodevelopmental delay. Recent publications detail variants in the AFF3 and ZMYM3 genes, as well as a novel pathogenic variant in the tumor protein p63 gene associated with Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome.
Sellars also contributes to the implementation of pharmacogenomics testing, examining experiences at Arkansas Children’s Hospital. Her work includes reviews of phenotypic and genetic data from multidisciplinary clinics, such as those focusing on craniofacial microsomia. Her scholarship metrics include an h-index of 17, with 38 publications and 1,378 total citations. She collaborates with researchers at the University of Arkansas for Medical Sciences, including Kevin Bielamowicz, Pritmohinder S. Gill, Jason Farrar, and Feliciano Yu.
Metrics
- h-index: 17
- Publications: 38
- Citations: 1,398
Selected Publications
-
Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome in monozygotic twins with a novel tumor protein p63 gene pathogenic variant (2025)
-
P288: A review of phenotypic and genetic data in craniofacial microsomia cases from a multidisciplinary craniofacial clinic (2025)
-
eP238: Inner epicanthal and nasal pits as presenting feature of holoprosencephaly (2022)
-
Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children’s Hospital (2021)
-
Variants in the degron of AFF3 are associated with intellectual disability, mesomelic dysplasia, horseshoe kidney, and epileptic encephalopathy (2021)
Grants & Funding
- Arkansas Reproductive Health Services Monitoring (ARHMS) UAMS ACHRI Flow Through Principal Investigator
- Arkansas Reproductive Health Services Monitoring (ARHMS) UAMS ACHRI Flow Through Principal Investigator
Collaboration Network
Top Collaborators
Susan M. Hiatt
HudsonAlpha Institute for Biotechnology (US)
3 shared publications
- Variants in the degron of AFF3 are associated with intellectual disability, mesomelic dysplasia, horseshoe kidney, and epileptic encephalopathy
- Deleterious, protein-altering variants in the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental delay phenotype
- Deleterious, protein-altering variants in the X-linked transcriptional coregulator <i>ZMYM3</i> in 22 individuals with a neurodevelopmental delay phenotype
Alfredo Brusco
University of Turin (IT)
3 shared publications
- Variants in the degron of AFF3 are associated with intellectual disability, mesomelic dysplasia, horseshoe kidney, and epileptic encephalopathy
- Deleterious, protein-altering variants in the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental delay phenotype
- Deleterious, protein-altering variants in the X-linked transcriptional coregulator <i>ZMYM3</i> in 22 individuals with a neurodevelopmental delay phenotype
Slavica Trajkova
University of Turin (IT)
2 shared publications
- Deleterious, protein-altering variants in the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental delay phenotype
- Deleterious, protein-altering variants in the X-linked transcriptional coregulator <i>ZMYM3</i> in 22 individuals with a neurodevelopmental delay phenotype
Matteo Rossi Sebastiano
University of Turin (IT)
2 shared publications
- Deleterious, protein-altering variants in the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental delay phenotype
- Deleterious, protein-altering variants in the X-linked transcriptional coregulator <i>ZMYM3</i> in 22 individuals with a neurodevelopmental delay phenotype
E. Christopher Partridge
HudsonAlpha Institute for Biotechnology (US)
2 shared publications
- Deleterious, protein-altering variants in the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental delay phenotype
- Deleterious, protein-altering variants in the X-linked transcriptional coregulator <i>ZMYM3</i> in 22 individuals with a neurodevelopmental delay phenotype
Fatima Abidi
Greenwood Genetic Center (US)
2 shared publications
- Deleterious, protein-altering variants in the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental delay phenotype
- Deleterious, protein-altering variants in the X-linked transcriptional coregulator <i>ZMYM3</i> in 22 individuals with a neurodevelopmental delay phenotype
Ashlyn G. Anderson
HudsonAlpha Institute for Biotechnology (US)
2 shared publications
- Deleterious, protein-altering variants in the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental delay phenotype
- Deleterious, protein-altering variants in the X-linked transcriptional coregulator <i>ZMYM3</i> in 22 individuals with a neurodevelopmental delay phenotype
Muhammad Ansar
Dow University of Health Sciences (PK)
2 shared publications
- Deleterious, protein-altering variants in the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental delay phenotype
- Deleterious, protein-altering variants in the X-linked transcriptional coregulator <i>ZMYM3</i> in 22 individuals with a neurodevelopmental delay phenotype
Stylianos E. Antonarakis
University of Geneva (CH)
2 shared publications
- Deleterious, protein-altering variants in the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental delay phenotype
- Deleterious, protein-altering variants in the X-linked transcriptional coregulator <i>ZMYM3</i> in 22 individuals with a neurodevelopmental delay phenotype
Azadeh Azadi
Golestan University of Medical Sciences (IR)
2 shared publications
- Deleterious, protein-altering variants in the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental delay phenotype
- Deleterious, protein-altering variants in the X-linked transcriptional coregulator <i>ZMYM3</i> in 22 individuals with a neurodevelopmental delay phenotype
Ruxandra Bachmann‐Gagescu
University of Zurich (CH)
2 shared publications
- Deleterious, protein-altering variants in the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental delay phenotype
- Deleterious, protein-altering variants in the X-linked transcriptional coregulator <i>ZMYM3</i> in 22 individuals with a neurodevelopmental delay phenotype
Andrea Bartuli
Bambino Gesù Children's Hospital (IT)
2 shared publications
- Deleterious, protein-altering variants in the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental delay phenotype
- Deleterious, protein-altering variants in the X-linked transcriptional coregulator <i>ZMYM3</i> in 22 individuals with a neurodevelopmental delay phenotype
Caroline Bénech
Université de Bretagne Occidentale (FR)
2 shared publications
- Deleterious, protein-altering variants in the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental delay phenotype
- Deleterious, protein-altering variants in the X-linked transcriptional coregulator <i>ZMYM3</i> in 22 individuals with a neurodevelopmental delay phenotype
Jennifer L. Berkowitz
2 shared publications
- Deleterious, protein-altering variants in the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental delay phenotype
- Deleterious, protein-altering variants in the X-linked transcriptional coregulator <i>ZMYM3</i> in 22 individuals with a neurodevelopmental delay phenotype
Michael J. Betti
Vanderbilt University Medical Center (US)
2 shared publications
- Deleterious, protein-altering variants in the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental delay phenotype
- Deleterious, protein-altering variants in the X-linked transcriptional coregulator <i>ZMYM3</i> in 22 individuals with a neurodevelopmental delay phenotype
Similar Researchers
Based on overlapping research topics
Jeffery L. Clothier
University of Arkansas for Medical Sciences
Genetics and Neurodevelopmental Disorders
Genomics and Rare Diseases
Metabolism and Genetic Disorders
Jeffrey Clothier
University of Arkansas for Medical Sciences
Genetics and Neurodevelopmental Disorders
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
G White
University of Arkansas for Medical Sciences
Genomics and Rare Diseases
Metabolism and Genetic Disorders
Birth, Development, and Health
David P. Douglass
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Birth, Development, and Health
Pharmacological Effects and Toxicity Studies
N Rowley
University of Arkansas for Medical Sciences
Genetics and Neurodevelopmental Disorders
Metabolism and Genetic Disorders
Birth, Development, and Health
Eniya Beemarajan
University of Arkansas for Medical Sciences
Genomics and Rare Diseases
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies